Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Boundless Bio

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Boundless Bio
Via Business Wire
Tickers BOLD
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
From Boundless Bio
Via Business Wire
Tickers BOLD
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
From Boundless Bio
Via Business Wire
Tickers BOLD
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
From Boundless Bio
Via Business Wire
Tickers BOLD
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
From Boundless Bio
Via Business Wire
Tickers BOLD
Boundless Bio Announces Pricing of Initial Public Offering
From Boundless Bio
Via Business Wire
Boundless Bio Announces Multiple Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024
From Boundless Bio
Via Business Wire
Boundless Bio Presents Preclinical Data on the Discovery of its Second ecDNA-Directed Therapeutic Candidate, BBI-825, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Boundless Bio
Via Business Wire
Boundless Bio Announces Upcoming Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Boundless Bio
Via Business Wire
Boundless Bio Appoints New Board Members and Establishes Clinical Advisory Board
From Boundless Bio
Via Business Wire
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors
From Boundless Bio
Via Business Wire
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate LYTGOBI® (futibatinib) in Combination with BBI-355 in Patients with FGFR Amplified Solid Tumors
From Boundless Bio
Via Business Wire
Boundless Bio Appoints Jami Rubin as Chief Financial Officer
From Boundless Bio
Via Business Wire
Boundless Bio to Present at the 2023 Jefferies Healthcare Conference
From Boundless Bio
Via Business Wire
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification
From Boundless Bio
Via Business Wire
Boundless Bio Presents Data on the Novel Discovery of CHK1 as an Extrachromosomal DNA (ecDNA) Essential Target in Oncogene Amplified Cancers at the American Association for Cancer Research Annual Meeting 2023
From Boundless Bio
Via Business Wire
Boundless Bio to Present at the Stifel 2023 Virtual Targeted Oncology Days
From Boundless Bio
Via Business Wire
Boundless Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Boundless Bio
Via Business Wire
Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2023
From Boundless Bio
Via Business Wire
Boundless Bio to Participate at Two Upcoming Investor Conferences
From Boundless Bio
Via Business Wire
Team Led by Boundless Bio Scientific Founders Receives $25M Award to Better Understand Extrachromosomal DNA (ecDNA) Through Cancer Grand Challenges
From Boundless Bio
Via Business Wire
Boundless Bio to Present at the 2022 Jefferies Healthcare Conference
From Boundless Bio
Via Business Wire
Boundless Bio Appoints Sara Weymer as Vice President, Clinical Operations
From Boundless Bio
Via Business Wire
Boundless Bio Presents Data on the Novel Discovery of the Association Between Extrachromosomal DNA (ecDNA) and Replication Stress at the American Association for Cancer Research Annual Meeting 2022
From Boundless Bio
Via Business Wire
Boundless Bio Appoints Klaus Wagner, M.D., Ph.D., as Chief Medical Officer
From Boundless Bio
Via Business Wire
Boundless Bio Appoints Amy Berkley, Ph.D., as Vice President, Program Team Leadership and Strategic Alliances
From Boundless Bio
Via Business Wire
Boundless Bio to Present at the Guggenheim Oncology Conference
From Boundless Bio
Via Business Wire
Boundless Bio Appoints Peter Krein, Ph.D., as Vice President, Precision Medicine
From Boundless Bio
Via Business Wire
Boundless Bio Appoints Jennifer Lew to its Board of Directors
From Boundless Bio
Via Business Wire
Boundless Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Boundless Bio
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.